Market cap
$30 Mln
Recently Viewed
Clear All$4.04
$-0.05
(-1.22%)
As on 05-May-2026 11:34EDT
Market cap
$30 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-1.8 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-1.4
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
7,250,487
CFO
$-56.85 Mln
EBITDA
$-23.84 Mln
Net Profit
$-46.83 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Briacell Therapeutics Corp (BCTX)
| -43.2 | -1.5 | -4.3 | -89.9 | -84.3 | -62.0 | -52.8 |
|
BSE Sensex
| -9.0 | 5.0 | -8.1 | -4.3 | 7.6 | 9.8 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Briacell Therapeutics Corp (BCTX)
| -91.6 | 35.2 | -47.2 | 98.6 | -57.6 | -37.5 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that... is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada. Address: Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1 Read more
CEO, President & Director
Dr. William V. Williams M.D.
CEO, President & Director
Dr. William V. Williams M.D.
Headquarters
West Vancouver, BC
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Briacell Therapeutics Corp (BCTX) is $4.04 (NASDAQ) as of 05-May-2026 11:34 EDT. Briacell Therapeutics Corp (BCTX) has given a return of -84.28% in the last 3 years.
Since, TTM earnings of Briacell Therapeutics Corp (BCTX) is negative, P/E ratio is not available.
The P/B ratio of Briacell Therapeutics Corp (BCTX) is 0.98 times as on 04-May-2026, a 68 discount to its peers’ median range of 3.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Briacell Therapeutics Corp (BCTX) are Rs 39.50 and Rs 3.60 as of 05-May-2026.
Briacell Therapeutics Corp (BCTX) has a market capitalisation of $ 30 Mln as on 04-May-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Briacell Therapeutics Corp (BCTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.